肺癌化疗多药耐药与逆转策略

Strategy of multidrug resistance and drug-resistance reversion in lung cancer chemotherapy

恶性肿瘤化疗失败的主要原因是多药耐药的发生。研究表明,多药耐药的机制十分复杂,P-gp、TopoⅡ、GST-π、金属硫蛋白(metallothionein,MT)及p53基因突变等是肺癌产生多药耐药的物质基础。本文重点介绍非小细胞肺癌耐药因子及耐药逆转的对策,以指导临床化疗药物的筛选及治疗方案的优化,有助于提高肺癌患者的生存期和生存率。

The main fail reason of malignant tumor chemotherapy is occurrence of multidrug resistance. It has been shown that the mechanism of multidrug resistance is much complicated. The material foundation of the multi-drug resistance in lung cancer was involved in P-gp, Topo Ⅱ , GST-π, Metallothionein, and p53 gene mutation etc. The aim of this report was to introduce the strategy of dragresistance factor and drug-resistance reversion in the non small cell lung cancer (NSCLC) to guide the choice of the clinical chemotherapy drug and the optimization of the regimens of treatment to NSCLC. It is beneficial to increase the patients with lung cancer to get out of survival period and survival rate.